Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4611 Management strategies and outcomes for type 1 gastric neuroendocrine tumours measuring > 1cm in diameter

Introduction: Although type 1 gastric neuroendocrine tumours (T1-gNETs) are usually considered indolent diseases, the management and the outcome of tumours >1cm remain not well established.

Conference:

Presenting Author:

Authors: Dell' Unto E, Srirajaskanthan R, Saini A, Salin G, de Mestier L,

Keywords: gastric neuroendocrine tumour, gastric carcinoid, endoscopic treatment,

#4526 The relationship between adherence to traditional Chinese medicine and disease progression in type 1 gastric neuroendocrine tumours: A case report

Introduction: Type 1 gastric neuroendocrine tumours (g-NETs) have a high recurrence risk after endoscopic resection, underscoring the need for regular endoscopic follow-up. Our research hints that Traditional Chinese Medicine (TCM) could help lower recurrence rates.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Cheng Z, Yu F, Chen R, Chen X,

Keywords: type 1 gastric neuroendocrine tumour, Traditional Chinese Medicine, regular follow-up, case report,

#4483 Metabolic parameters and visceral adiposity index in type 1 gastric neuroendocrine tumours: A single-centre cross-sectional study

Introduction: Studies have shown that the accumulation of visceral fat and the occurrence of metabolic syndrome (MetS) lead to disruptions in immune-metabolic crosstalk, contributing to the development and progression of autoimmune diseases and well-differentiated gastric neuroendocrine tumours (gNETs).

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen R, Wang Y, Wang Y,

Keywords: Type 1 gastric neuroendocrine tumour, Metabolic Syndrome, Visceral Adiposity Index,

#4456 Characteristics and clinical outcomes after endoscopic or surgical resection of localised sporadic type III gastric NETs: A national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network

Introduction: Type III gastric neuroendocrine tumours (gNETs) are rare indolent tumours with increasing incidence. Endoscopic resection has recently been described to be a safe strategy to remove small, localised type III gNETs.

Conference:

Presenting Author: Perrier M

Authors: Perrier M, Lefort R, Do Cao C, Hautefeuille V, Wallenhorst T,

Keywords: neuroendocrine neoplasm, stomach, endoscopy, surgery, carcinoid,